• Laredo Oil Inc. is an oil and gas E&P company engaged in acquiring, developing and operating both conventional oil and gas properties and select mature oil fields that are suitable for the use of the company’s proprietary EOR methods
• Regardless of the property, the company focuses on value, growth upside and free cash flow
• Laredo Oil has acquired leases on 23,739 mineral acres in Montana
• Laredo Oil has identified 10 initial drilling locations, with the intention to drill the first development well in calendar 2021

Laredo Oil (OTC: LRDC) is a publicly traded oil and gas exploration and production (E&P) company engaging in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields that are suitable for the company’s proprietary Enhanced Oil Recovery (“EOR”) methods. Laredo Oil is headquartered in Austin, Texas. Conventional Acreage Laredo Oil’s primary focus is on acquiring, developing, and operating undervalued conventional oil and gas properties. The company leased 23,739 mineral acres in the Western Williston Basin of Montana, at favorable prices during the most recent down cycle and continues to take leases in the area. Before year end, it expects to drill the first development well at one of the first of 10 potential locations it has identified. If that well yields the anticipated results, the company plans to begin drilling additional wells there as soon as practical thereafter. The company believes the leased acreage has the potential to yield at least five years of development opportunities. The company intends to pursue aggressively the acquisition of quality assets that major, mid-major, and large independent oil and gas companies continue to divest themselves of at a discount in response to ESG (Environmental, Social and Governmental) & sustainability initiatives and other pressures imposed upon them by their activist boards of directors. The company will focus on value, growth potential and free cash flow while complying with common sense ESG policies, often having a lower environmental impact than its competitors through its EOR methods. EOR In addition to pursuing conventional acreage and properties, Laredo Oil plans to acquire additional select mature oil fields where it believes that it can profitably use its proprietary Underground Gravity Drainage(TM) (“UGD”) model to recover stranded oil reserves (reserves previously considered to be economically incapable of recovery). The UGD method is applicable to mature oil fields that have very specific geological and reservoir characteristics. Laredo Oil has done extensive research and field level application over the last 10 years and has identified specific oil fields within the United States that it believes are qualified for the UGD recovery method. The company believes the costs of implementing the UGD method are significantly lower than those of other commonly used EOR methods. Laredo Oil believes that it can materially increase the field oil production rate from prior periods and, in some cases, recover amounts of oil equal to or greater than amounts previously recovered from the mature fields selected. Market Outlook The company expects U.S. oil prices to climb in the near term as energy demand intensifies with the economy continuing to recover from the COVID-19 slowdown. Also causing upward price pressure is global supply chain dysfunction that slows or prevents shipments, including energy components, from reaching destinations. Domestic oil production is also constrained by years of reduced investment in fossil fuel producers due to green energy mandates. Accordingly, the company believes that the short-term outlook for oil is favorable. Many industries have yet to reach their pre-COVID production levels, which the company believes points to a continuing near-term upward trend in energy demand. Management Team Mark See has been the Chief Executive Officer and Chairman of the Board of Directors of the company since October 16, 2009. He has over 30 years’ experience in heavy civil, natural resources and the E&P industries. He was the founder and founding CEO of Rock Well Petroleum, a private oil & gas company until December 2008 and worked from then until October 2009 forming Laredo Oil. He was employed with Albian Sands as the Manager for the Alberta Oil Sands Projects at Fort McMurray, Alberta, Canada, a joint venture between Shell Canada and Chevron. Mr. See was also President of Oil Recovery Enhancement LLC in Bozeman, Montana, a private oil company. He was selected as one of the top 25 Engineers in North America by the Engineering News Record for his innovations in the petroleum industry. He is a graduate of the Mackay School of Mines at the University of Nevada at Reno, with a degree in Mining Engineering. He is a member of the Society of Mining Engineers and the Society of Petroleum Engineers. Bradley Sparks currently serves as the Chief Financial Officer and Treasurer of Laredo Oil and has been a director of the company since March 1, 2011. Before joining Laredo Oil in October 2009, he was the Chief Executive Officer, President and a Director of Visualant Inc. Prior to joining Visualant, he was the Chief Financial Officer of WatchGuard Technologies Inc. from 2005-2006. Before joining WatchGuard, he was the founder and managing director of Sunburst Growth Ventures LLC, a private investment firm specializing in emerging-growth companies. Previously, he founded Pointer Communications and served as Chief Financial Officer for several telecommunications and internet companies, including eSpire Communications Inc., Digex Inc., Omnipoint Corporation, and WAM!NET. He also served as Vice President and Treasurer of MCI Communications from 1988-1993 and as Vice President and Controller from 1993-1995. Before his tenure at MCI, Mr. Sparks held various financial management positions at Ryder System Inc. He currently serves on the Board of Directors of Comrise. Mr. Sparks graduated from the United States Military Academy at West Point in 1969 and is a former Army Captain in the Signal Corps. He has a Master of Science in Management from the Sloan School of Management at the Massachusetts Institute of Technology and is a licensed CPA in Florida. Donald Beckham has served as a director of the company since March 1, 2011. Since July 2015, he has been a partner with Copestone Energy Partners LLC. In 1993, he founded Beckham Resources Inc. (“BRI”), which, for over 30 years, has been a licensed, bonded and insured operator in good standing with the Railroad Commission of Texas. Through BRI, Mr. Beckham has drilled and operated fields for his own account. His expertise is in the acquisition, exploitation, exploration and production enhancement of mature oil and gas fields through which he has been able to enhance production by compressor optimization, pump design, work-over programs, stimulation techniques and identifying new pay zones. Prior to BRI, Mr. Beckham was the chief operations manager for Houston Oil Fields Corporation (“HOFCO”), where he began his career. There, he was responsible for drilling, production and field operations and managed approximately 100 people, including engineers, geologists, land men, pumpers, and other contract personnel, as well as state and federal environmental and regulatory functions. He managed an annual capital budget of approximately $30 million and operated approximately 100 wells. HOFCO drilled about 20 wells per annum and performed approximately 30 recompletions and work over operations each year. HOFCO owned interests in about 10 key fields principally in Texas, and company-managed production was approximately 1,000 bpd of crude oil and 10 mm cfd of natural gas. Mr. Beckham is a petroleum engineer and 1984 graduate of Mississippi State University. Michael Price, an independent director of Laredo Oil, has over 40 years of senior financial and petroleum experience in the global oil and gas industry. He has been a principal in Octagon Energy Advisors, a Houston-based energy investment advisory firm, from 2002 to the present. The firm advises financial institutions and institutional investors participating in energy investments. From 2008 through his retirement in 2021, he was a Managing Director at ING Capital, which provides debt financing to domestic exploration and production companies. From 1998 through 2002, Mr. Price was the Chief Financial Officer of Forman Petroleum Corporation. Before that, Mr. Price was Managing Director at Chase Manhattan Bank for 15 years and was in charge of technical support for Chase’s worldwide energy merchant banking activities. In his early career, he worked as a consulting principal on domestic petroleum engineering and landowner matters and gained extensive international experience working with major oil companies in a variety of operating positions. He holds a BS and MS from Illinois Institute of Technology, an MBA from the University of Chicago, a M.Sc. from the London School of Economics, and an MS in Petroleum Engineering from Tulane University. For more information, visit the company’s website at www.Laredo-Oil.com. NOTE TO INVESTORS: The latest news and updates relating to LRDC are available in the company’s newsroom at https://ibn.fm/LRDC

• The COP26 climate change summit is taking place Oct. 31-Nov. 12 in Glasgow at the Scottish Event Campus (“SEC”) after being delayed last year due to the COVID-19 pandemic
• The overall consensus worldwide is to strive for zero emissions by 2050 – requiring energy solutions that emit no greenhouse gases and are environmentally sustainable
• FuelPositive’s modular and scalable carbon-free ammonia system offers more hydrogen than highly compressed hydrogen and is highly competitive with other methods of replacing fossil fuels
• The green ammonia market is expected to grow at a CAGR of 54.9% over the next decade

After being postponed because of the COVID-19 pandemic last year, the COP26 climate change summit is taking place Oct. 31 – Nov. 12, at the Scottish Event Campus (“SEC”) in Glasgow. Discussing the importance of the climate change summit, the chair of the Energy Transitions Commission, Adair Turner, highlighted the role of companies and governments in reducing emissions. In a CNBC Europe interview, Turner, who served as chair of UK’s Financial Services Authority between 2008 and 2013, stated that “almost everybody has now agreed that we’ve got to get the global economy to about zero emissions by 2050.” He also talked about how renewable technologies, batteries and electrolyzing hydrogen are far more inexpensive than originally thought a decade ago (https://ibn.fm/GYKoa). Even though green hydrogen is the overall goal, the industry still faces many difficulties. Producing hydrogen is energy-intensive, and the end product is highly volatile. At normal temperatures, hydrogen escapes and leaks into the structure of metals, making them brittle. Storing hydrogen is also complicated because it requires extreme pressure for proper storage. There is virtually no infrastructure available and no safety precautions in place for the distribution and transportation of hydrogen. Toronto-based FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) offers an alternative to hydrogen distribution issues through its proprietary on-site production of carbon-free ammonia (“NH3”) technology. FuelPositive’s NH3 system is more energy-efficient than conventional forms of NH3 but without carbon emissions. The system also yields 65% more hydrogen than highly compressed hydrogen products, because the ammonia molecule is so stable there is no “boiling off,” no extreme compression required, and no cracking of brittle metals. FuelPositive recently closed its subscription agreement with certain U.S. institutional investors with gross proceeds totaling approximately CAD$7 million (USD$5.66 million). This private placement in the U.S. consists of 30,434,784 common shares and warrants to purchase up to the same amount of common shares for CAD$0.23 (USD$0.19) per common share and warrant. The warrants have an exercise price of CAD$0.25 (USD$0.20) per common share until Oct. 28, 2024. The proceeds from the sale of shares will be used to help deploy more of FuelPositive’s carbon-free ammonia systems into high-profile demonstration projects throughout 2022. Funding may also be used for general corporate purposes as well. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement in the U.S. (https://ibn.fm/P46uh) FuelPositive’s flagship modular and scalable carbon-free ammonia technology was developed by Dr. Ibrahim Dincer and his esteemed team at Ontario Technology University in Toronto. The platform will allow for in-situ production of NH3 sustainably. The process involves using only water, air and sustainable electricity. Through its proprietary technology, FuelPositive is on track to create a viable option for replacing traditional fossil fuels, while also becoming a leading provider on the expanding green ammonia market. The industry is expected to grow at a CAGR of 54.9% over the next decade. The increase can largely be attributed to the global goal of utilizing green ammonia as a fossil fuel replacement over the next 30 years. (https://ibn.fm/ym2Af) For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Health diagnostics solutions provider Avricore Health has established neighborhood lab-accurate medical condition testing platform in 15 sites in Ontario through the Shoppers Drug Mart network earlier this year
• Now Avricore has announced an expansion through the Shoppers Drug Mart agreement to serve five cities in British Columbia
• Avricore’s trademarked HealthTab network partners with pharmacies, kiosk developers and analytical instrument makers to provide patients ready access to data for managing their health in real time with the oversight of trained health professionals
• The point-of-care testing market is expected to generate revenues of $50.6 billion by 2025 as consumers seek more direct involvement in managing their wellness and a means of avoiding the costs and wait times associated with doctors’ office visits

After successfully rolling out a point-of-care health diagnostic platform in a group of Ontario pharmacies, technology innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is expanding to Canada’s west coast where its product can reach a new market and evaluate the needs of a diverse patient population. Avricore’s flagship HealthTab (TM) platform is a solution that conveniently generates lab-accurate results for select medical conditions and communicates them in real time with patients as well as with trained health care professionals. The platform teams up with neighborhood pharmacies, kiosk station builders and analytical instrument makers to provide patients with the ability to give a simple sample of blood and obtain prompt health management results at accessible pharmacy locations, potentially reducing costs and waiting times associated with busy doctors’ offices and clinics. Through cloud-based technology, the HealthTab platform provides data to the patients’ doctors to facilitate any needed follow-up care. HealthTab’s diagnostic menu screens for up to 23 key biomarkers associated with chronic diseases such as diabetes and heart disease, and now also includes testing for bacteria and viruses such as strep and COVID-19. Avricore initially provided HealthTab services to patients at 15 Ontario pharmacies thanks to a pilot agreement with the Shoppers Drug Mart network. The expansion announced Oct. 26 adds five cities in British Columbia — Richmond, Burnaby, Vancouver, Surrey, and Victoria (https://ibn.fm/pMQqo). The outlets represent a small fraction of Shoppers Drug Mart’s 1,800-pharmacy network, and Avricore says it plans to serve 600 locations by the end of 2023. “Patient feedback, along with that of our pharmacists, has been very positive in Ontario with respect to HealthTab and we are evaluating how more patients can benefit from this type of service,” Shoppers Drug Mart Director of Complex Care Frank Hack stated in the news release. “In coming to British Columbia, we are hoping to learn more about patient needs and serve them in the best way possible.” Avricore anticipates eventually placing its product in other pharmacies in the United States, the United Kingdom and the European Union. “The nice thing is all this technology that we use, everything that we’re doing down there (in the United States), is already approved so we are not at a sort of regulatory or approval risk at any level expanding internationally,” Avricore CEO Hector Bremner said during a recent podcast interview (https://ibn.fm/0q2qB). “We’re also really excited about opportunities in the UK and EU, which, I think people just don’t understand how big a market that really is — it’s still bigger than China and it is a place where I think we can do business reliably. Between the U.S., UK and Canada, there’s about 110,000 pharmacies.” The five cities in British Columbia have already received HealthTab devices ready to analyze for known conditions associated with pre-diabetes, or patients already identified as diabetic to help with management of their condition. By the end of the decade, nearly 13.6 million Canadians are expected to be diabetic or prediabetic — many of them undiagnosed by a physician — according to a report last year by national health charity Diabetes Canada (https://ibn.fm/47Fj4). Analysts at Markets and Markets expect point-of-care testing revenue potential to reach $50.6 billion by 2025, with glucose monitoring for diabetes comprising the largest growing sector of the market (https://ibn.fm/VWziB). For more information on Avricore Health, visit the company’s website at http://www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly listed Ginkgo Bioworks Holdings Inc., in what is the largest-ever biotechnology go-public transaction
• Ginkgo Bioworks is known for its work in the commercial-scale production of a rare cannabinoid, CBG, for use in a multitude of industrial needs
• InMed uses multiple manufacturing approaches to synthetically produce rare cannabinoids, including CBC which is currently sold through its subsidiary BayMedica
• The success of the Ginkgo IPO suggests the marketplace value associated with the production of rare cannabinoids

Special purpose acquisition company (“SPAC”) Soaring Eagle Acquisition Corp. (NASDAQ: SRNGU, SRNG, SRNGW) recently announced a business combination between itself and Ginkgo Bioworks. The resulting entity made its debut renamed as Ginkgo Bioworks Holdings, Inc. and a public listing on the New York Stock Exchange (“NYSE”) under the ticker symbol DNA. A total of 75% of Soaring Eagle’s shareholders participated in the vote, with 97% of them voting in favor of the combination. The combination closed on September 16, 2021, with the public trade on the NYSE commencing the following day. The $1.6 billion in proceeds from the combination represents the largest biotechnology go-public transaction to date (https://ibn.fm/OSP4s). In recent news, Ginkgo Bioworks announced that the company had made a breakthrough improvement on how they produce a key material used in mRNA vaccine manufacturing and the commercial-scale production of the rare cannabinoid CBG. Like Ginkgo Bioworks, biopharmaceutical company InMed Pharmaceuticals Inc. (NASDAQ: INM) and its subsidiary BayMedica are innovators in the field of rare cannabinoids, making them available for consumer access. InMed specializes in developing a proprietary biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids that are otherwise too rare to be acquired in abundance. Also, through their recent acquisition of BayMedica, InMed now has capabilities in both yeast biosynthesis and chemical synthesis, catering to the large and growing health and wellness consumer markets. The cannabis plant is made up of over 100 unique cannabinoids, many of which are only found in trace amounts. The initial focus of InMed is the therapeutic benefits of a cannabinoid named cannabinol (“CBN”), which may be helpful in numerous diseases that have a high unmet medical need. With CBN being found in such small amounts in the cannabis plant, InMed is developing IntegraSyn to help create the cannabinoid synthetically in the lab. Currently, InMed has two drugs within its pipeline using CBN — INM-755 and INM-088. INM-755 is a topical compound with CBN to be used for the treatment of epidermolysis bullosa, a severe genetic skin disorder. INM-755 has already been evaluated in two phase I clinical trials, and recently commenced a global phase II study. INM-088 is an ocular CBN treatment for glaucoma. When applied directly to the eye, INM-088 has shown significant promise in reducing intraocular pressure and providing neuroprotection of the eye. With so many of these cannabinoids exhibiting the potential to fulfill several unmet medical needs industry-wide, InMed is working on the answer to mass production of rare and otherwise depleted cannabinoid opportunities. Unlike tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”), which are found in excess within the cannabis plant, the goal for InMed and its subsidiary BayMedica is to use various manufacturing approaches to produce the amounts of rare cannabinoids necessary to fulfill the outstanding medical need in the industry. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

New York’s recreational marijuana market is poised to begin with a bang — and the Cannabis World Congress & Business Exposition (“CWCBExpo”), which is being held at New York City’s Javits Convention Center, Hall 3A between 4-6 November 2021, is the ideal forum for education, business building and networking on this multifaceted industry. As of Sept. 21, 2021, adult New Yorkers are now able to possess up to three ounces of cannabis for recreational use or up to 24 grams of concentrated cannabis, such as oils derived from a cannabis plant (https://ibn.fm/fo1Cr). With the state’s cannabis industry expected to begin licensed sales from around 2023 onwards, industry entrepreneurs have forecast the sector to generate up to $1.1 billion in revenues within its first year of operations (https://ibn.fm/2u9vJ). Cannabis decriminalization is set to lead to plenty of jobs and tax revenue; according to cannabis marketplace platform, Leafly Holdings Inc., up to 20,000 full time jobs are expected to be created within the first 18 months of legal sales, rising to approximately 60,000 positions within five years. Meanwhile, Leafly forecasts that annual sales for the sector will reach $3.5 billion in the five years post legalization, resulting in tax revenues of approximately $450 million for the state of New York. The CWCBExpo, which has long established a reputation as a leading forum for dispensary owners, growers, suppliers, investors, medical professionals, government regulators, legal counsel, and entrepreneurs looking to achieve business success and identify new areas of growth, has positioned itself as the ideal starting point for entrepreneurs and investors seeking to establish a foothold in New York’s promising cannabis sector. Segmented into three daily sessions– covering “Where We Are Today”, “Challenges & Solutions” and “What’s Next?”, respectively, the conference will seek to address a number of pertinent issues surrounding the ongoing changes within the sector. Topics to be covered include: A full list of the presentation topics to be covered over the three-day event can be found at: https://ibn.fm/KrOe8. In addition to the conference’s wide array of expert speakers and industry thought leaders, the summit will also play host to hundreds of exhibitors set to feature some of the industry’s latest innovations, products and services. Attendees will also be able to participate in an industry networking event, “Back-to-Business Celebration,” which will be held immediately post the first day of the CWCBExpo, wherein conference delegates will be able to network and further their interactions with their fellow peers. For more information about the CWCBExpo, visit www.CWCBExpo.com.

Date: November 2 – 4, 2021 Live Streaming Traders, investors, shareholders and businesses are invited to attend the Interactive MoneyShow Virtual Expo on November 2-4, 2021. MoneyShow has been organizing conferences and seminars for over 40 years with a 100,000+ community of investors, financial heads and businesses looking to gain knowledge and guidance about the latest investment tools, financial trends and opportunities from the stalwarts of the financial arena. The event presents a wonderful opportunity for traders and investors to interact with financial leaders and company experts via interactive message boards. The educational videos and articles serve as a source of a huge knowledge base for new traders, shareholders and investors seeking guidance on the management of investments and growth opportunities in the financial trading segment. The Interactive MoneyShow Expo showcases influential speakers who are eminent personas in their niche. Exhibitors can host live presentations and explain their product and service line in the Virtual Exhibit Hall while availing of great discounts and win numerous prizes in different events. This Virtual Exhibit Hall is a tremendous marketing forum where investors from different backgrounds understand your business and you get an opportunity to develop a long-term association with them. Attendees can participate for free to watch the interactive sessions and live presentations by distinguished financial leaders. These dignitaries will discuss who they are adapting their trading and investment plans as per the current market trends. They will also offer their insights and tips into the future course of action on stocks, bonds and ETFs to options, futures, forex, and more. The interactive sessions offer an in-depth analysis of the current trends so that you can make better trading and investment decisions to enjoy better profits. Inflation will be an important agenda of discussion at the expo where attendees can get valuable guidance and key pointers for managing their investments in the current environment. Presentations will also include detailed explanations on how we can use non-dividend stocks and create our dividend-like cash flow by selling call options. The speaker sessions will be followed by real-life examples as to how to implement option-selling to create a dividend-like cash flow with non-dividend bearing stocks. To know more about the event, please visit https://ibn.fm/Q278k

• FingerMotion, through its subsidiary, JiuGe, announced two new brands- Ji Shi Fu and Baowo
• These brands will offer device protection services to telecom customers within China
• JiuGe is targeting the integration of these services by early 2022
• FingerMotion is confident that the new additions will allow it to monetize its vast active user base further

FingerMotion (OTCQX: FNGR), through its subsidiary, Shanghai JiuGe Information Technology Co., has announced the introduction of a new service — an innovative device protection program for telecom customers within the Chinese market. JiuGe announced the trademarking of two new brands, “Ji Shi Fu” and “Baowo,” that will offer maintenance on broken mobile phone screens, accidental damage repairs, compensation, and older device trade-ins (https://ibn.fm/nR3NF). Having studied foreign markets and how the servicing industry is thriving, JiuGe is confident that there is tremendous, largely untapped potential in this sector, specifically within the Chinese market. The goal is to cover a portion of the hundreds of stores across ten different provinces by early 2022, with the assistance of a large American insurance company. Preliminary beta testing commences in late October 2021 and will be conducted in Guangdong, Shanghai, Anjui, Henan, and Zhejiang provinces and cities (https://ibn.fm/nR3NF). More details will be announced once the testing is done. This move provides a new way for FingerMotion to monetize its large user base and capitalize on a largely untapped market. Additionally, it complements its already-existing line of products and services, allowing the company to offer more value to its customers while also increasing their overall lifetime value. “This latest development demonstrates the flexibility of our business model to explore ways to monetize our vast active user base. We are delighted to commence our beta testing on this mobile device protection product later this month and believe this will eventually present another significant revenue stream,” noted Martin Shen, the chief executive officer (“CEO”) of FingerMotion (https://ibn.fm/nR3NF). For more information, visit the company’s website at www.FingerMotion.com NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Although the U.S. has yet to adopt cryptocurrency as a form of payment, other countries have begun the adoption process
• Mastercard will be one of the first major credit card companies to convert to cryptocurrency instead of a point system. The bitcoin can be used to get airline miles, hotel stays, gift cards, and more.
• In 2020, it was estimated that 328,370 bitcoin transactions go through each day, with approximately 15,174 businesses accepting crypto as a form of payment
• LQwD’s Lightning Network helps to send bitcoin payments, providing quicker settlement times and fewer user fees

Since the introduction of bitcoin, cryptocurrency has been steadily increasing in popularity among users. The rise in popularity promoted an increasing number of businesses and institutions to adopt digital currencies. Even some countries, such as El Salvador, have begun accepting bitcoin as a form of currency. Although the United States has yet to commit itself to crypto, major credit card company Mastercard announced plans to incorporate bitcoin and other cryptocurrencies into its payment and banking platform (https://ibn.fm/YLd0l). Most banks and credit card companies reward members with points. These points can be redeemed for rewards, like airline miles, gift cards, and more. With digital currency in the mix, customers will be given cryptocurrency, which can grow or shrink in value based on the market. It is also likely that existing member points will be able to be converted to cryptocurrency. Mastercard’s integration couldn’t come at a better time. The crypto market, especially bitcoin, is booming. In 2020, it was estimated that 328,370 bitcoin transactions went through each day – with approximately 15,174 businesses accepting crypto as a form of payment. The market growth and increased adoption are benefitting digital payment companies such as LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF), a financial tech firm focused on creating an enterprise-grade infrastructure to drive bitcoin adoption. LQwD’s Lightning Network is a platform as a service (“PaaS”) that users leverage to send payments instantly, securely, and with as little expense possible to anywhere in the world. By integrating LQwD’s infrastructure into their business, companies can network transactions in bitcoin. The Lightning Network nodes can be deployed, monitored and managed with little to no technical knowledge required. A viable solution for massively scaling bitcoin for microtransactions around the globe, the network also helps reduce fees and offers instant settlement times. LQwD sees the Lightning Network as an enabling technology that will bring bitcoin to hundreds of millions of users worldwide, thus further driving the company’s sustained growth. For more information on LQwD and the Lightning Network, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Flora Growth Corp. is an international cannabis consumer packaged goods distributor and cultivator based in Colombia that has built an ecosystem that will support market-leading innovation within categories that matter most to consumers exploring plant-based consumer goods.
• The company recently obtained the Good Agricultural and Collection Practices (“GACP”) certification from international certification agency and global leader in medical cannabis certification Control Union Medical Cannabis Standard (“CUMCS”)
• Flora Growth also just announced the launch of a new brand named Munzhi that will initially provide 12 CBD products for wellness, hair, body, and face benefits
• Flora Growth’s Colombian operations are already producing more than 190 products, 63 of which are INVIMA-registered over-the-counter (“OTC”) products and have received three GMP certifications from the agency regulating Colombia’s food and drug trade

International cannabis brand builder and cultivator Flora Growth Corp. (NASDAQ: FLGC) is preparing to expand its global footprint with the development of a new collection of cannabidiol (CBD) wellness lifestyle products. Flora Growth’s Flora Lab division is launching the new Munzhi brand with 12 products across four categories: Wellness, Hair, Body, and Face. Launch efforts have been initially focused on the Colombian market, though the company will also be selling through an online shop and shipping around the world. Colombian President Ivan Duque loosened the country’s limits on cannabis trade in July, permitting the export of dry cannabis flowers used in food, beverage, cosmetics and textiles markets, and delivering Colombian countries confidence that they can leap into Europe’s and North America’s pharmaceutical markets, according to a CNN news report (https://ibn.fm/rilT5). Flora Growth has already established a cultivation and processing base in Colombia. The company bought 100 hectares — about 247 acres — in central Colombia and has established production at this base, named Cosechemos, at a cost the company estimates to be around 6 cents per gram of dried cannabis flower, a fraction of the go-to price that ranges from 50 cents to $2 in the United States, according to the news report. The Munzhi brand combines CBD as an active ingredient with other plant-based ingredients such as lavender oil and chamomile coconut for a facial serum, shampoo, conditioner, shower gel, body ointment and a moisturizing lotion, with plans to expand product offerings over time. “Through market studies, consumers have indicated they want the wellness benefits of cannabis, but at an affordable price. Munzhi helps fill that need as well as an important gap in our product portfolio,” Flora Growth President and CEO Luis Merchan stated in a news release about Munzhi (https://ibn.fm/1U1fN). Flora Lab recently received its cosmetics GMP certification from Colombia’s food and drug regulatory agency Instituto Nacional de Vigilancia de Medicamentos y Alimentos (“INVIMA”) — its third GMP certification overall — and now serves as Flora Growth’s division for R&D and manufacturing of pharmaceuticals, cosmetics, and nutraceuticals. The lab operates a modern, 16,000-square-ft manufacturing facility that produces more than 190 products, 63 of which are INVIMA-registered over-the-counter (“OTC”) products. With the three GMP certifications, Flora Growth can pursue distribution agreements for products that contain CBD as well as non-CBD products in markets where access requires GMP certification (https://ibn.fm/A1Ety). The company has more than 2,500 global distribution channels through pharmacies and wholesale clients and aims to continuing expanding them. Neighbor country Panama recently passed legislation legalizing medical cannabis (https://ibn.fm/8JEZt) and Flora Growth’s non-binding LOI with Panamanian importer and distributor Robust Farms Inc. promises to grant Flora a pipeline into that market (https://ibn.fm/MIgdg). On Oct. 25, Flora Growth announced it has received the Good Agricultural and Collection Practices (GACP) certification by the Control Union Medical Cannabis Standard (“CUMCS”), a leading international certification agency and global leader in medical cannabis certification. “In advance of this milestone, our team has signed several LOI’s for the sale and distribution of dry flower and derivative products to several international jurisdictions, including the EU, Australia, and Latin America,” Flora’s Chief Revenue Officer Jason Warnock stated (https://ibn.fm/Qg5jz). “We are now in the position to unlock the significant potential from Cosechemos as we continue building our global distribution network.” For more information, visit Flora Growth’s website at https://floragrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• In July, Tryp appointed Dr. Robin Carhart-Harris as the Chairman of its Scientific Advisory Board and Dr. Daniel Clauw, M.D., as a member
• Commenting on the appointments, Tryp Chairman and CEO Greg McKee expressed his appreciation at the pair’s commitment to the alleviation of chronic pain and other diseases with psychedelic-based therapies as well as the company
• Fibromyalgia affects millions globally, but existing approved treatments have limited efficacy and/or cause significant side effects
• Tryp aims to remedy this, alleviating the suffering of millions of patients

In February of 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company, appointed Dr. Robin Carhart-Harris to its Scientific Advisory Board (“SAB”) (https://ibn.fm/jSASb). The founder of the first-of-its-kind Center for Psychedelic Research at Imperial College London and the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco, Dr. Carhart-Harris continues to be instrumental in advising Tryp through the development of its psilocybin programs. In July, (https://ibn.fm/NkpfQ), Tryp also appointed Dr. Daniel Clauw, M.D. as a new member of the board. A Professor of anesthesiology, medicine (Rheumatology), and psychiatry at the University of Michigan, Dr. Clauw serves as the Director of the university’s Chronic Pain and Fatigue Research Center. He is also a world-renowned expert on fibromyalgia and nociplastic pain. “I would like to thank Dr. Robin Carhart-Harris and Dr. Daniel Clauw for their persistent commitment not only to Tryp but also to the alleviation of chronic pain and other diseases with psychedelic-based therapies,” said Tryp Chairman and CEO Greg McKee following the July appointments. Dr. Clauw’s commitment and work are captured in a 2020 Scientific American article titled “The Unexpected Diversity of Pain” (https://ibn.fm/NNuXh). The article, which discusses three types of pain (nociceptive, neuropathic, and nociplastic), noted that Dr. Clauw is passionate about helping people with nociplastic pain, a kind of long-misunderstood pain that could underpin chronic conditions, including fibromyalgia. According to the article, nociplastic pain “results from no obvious inflammation or injury. Rather, it’s as if the volume knob for pain is turned up way too high, not at the pain site itself but further afield.” This type of pain appears to originate in parts of the central nervous system – the brain or spinal cord – that receive, transmit, or process pain signals. “These nerves misfire, creating a sensation of pain even though nothing may be wrong. The localization of the problem, the central nervous system, is why Clauw prefers to call it ‘central sensitization.’ The classic example is fibromyalgia, which causes pain that seems to stem from muscles, tendons, and joints, despite the real problem lying in the brain or spinal cord,” explained the article. According to Tryp’s internal analysis, over 4 million people suffer from fibromyalgia in the United States. Globally, the condition affects an estimated 3-6% of the population (roughly 232-465 million people) (https://ibn.fm/AR0oK). Unfortunately, despite the disease afflicting millions, researchers have not yet made substantial gains in treating fibromyalgia at its origin. Existing FDA approved treatments, for example, have limited efficacy and/or significant side effects. Tryp is looking to change this narrative. Through the guidance of its SAB, which also includes Joel Castellanos, M.D., Rachel Wervick, Ph.D., Derek Ott, M.D., and William Schmidt, Ph.D., coupled with research-based work conducted in collaboration with the University of Michigan, Tryp hopes to transform the existing treatment of fibromyalgia, along with other forms of chronic pain, and relieve the suffering of millions of patients. To this end, Tryp recently announced that it expects to file a separate Investigational Drug (“IND”) application before the end of October for its Phase 2a study in fibromyalgia through a collaboration with the University of Michigan (https://ibn.fm/jweV9). Having already received IND authorization for a Phase 2a clinical trial in phantom limb pain, Tryp is moving forward with the academic collaboration for this condition. In addition, the company is continuing to advance the partnership for a Phase 2a clinical trial in complex regional pain syndrome. Meanwhile, Tryp announced that the FDA had placed a clinical hold on its Phase 2a study for eating disorders, including binge eating disorder and hypothalamic obesity. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF